- Home
- OMER vs FRGE Comparison
OMER vs FRGE Comparison
Compare OMER & FRGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMER
- FRGE
- Stock Information
- Founded
- OMER 1994
- FRGE 2014
- Country
- OMER United States
- FRGE United States
- Employees
- OMER N/A
- FRGE N/A
- Industry
- OMER Biotechnology: Pharmaceutical Preparations
- FRGE Computer Software: Prepackaged Software
- Sector
- OMER Health Care
- FRGE Technology
- Exchange
- OMER Nasdaq
- FRGE Nasdaq
- Market Cap
- OMER 188.1M
- FRGE 175.1M
- IPO Year
- OMER 2009
- FRGE N/A
- Fundamental
- Price
- OMER $3.65
- FRGE $16.77
- Analyst Decision
- OMER Strong Buy
- FRGE Buy
- Analyst Count
- OMER 5
- FRGE 5
- Target Price
- OMER $18.00
- FRGE $38.25
- AVG Volume (30 Days)
- OMER 936.6K
- FRGE 109.2K
- Earning Date
- OMER 08-06-2025
- FRGE 08-06-2025
- Dividend Yield
- OMER N/A
- FRGE N/A
- EPS Growth
- OMER N/A
- FRGE N/A
- EPS
- OMER N/A
- FRGE N/A
- Revenue
- OMER N/A
- FRGE $85,383,000.00
- Revenue This Year
- OMER N/A
- FRGE $18.22
- Revenue Next Year
- OMER $468.75
- FRGE $29.35
- P/E Ratio
- OMER N/A
- FRGE N/A
- Revenue Growth
- OMER N/A
- FRGE 16.04
- 52 Week Low
- OMER $2.95
- FRGE $6.60
- 52 Week High
- OMER $13.60
- FRGE $24.45
- Technical
- Relative Strength Index (RSI)
- OMER 54.74
- FRGE 48.69
- Support Level
- OMER $3.00
- FRGE $17.48
- Resistance Level
- OMER $3.25
- FRGE $19.94
- Average True Range (ATR)
- OMER 0.24
- FRGE 0.96
- MACD
- OMER 0.10
- FRGE -0.30
- Stochastic Oscillator
- OMER 83.33
- FRGE 12.03
About OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
About FRGE Forge Global Holdings Inc.
Forge Global Holdings Inc is a financial service platform created to serve the needs of the private market. It provides marketplace infrastructure, data services, and technology solutions for private market participants. The company offers a trusted trading platform, proprietary data and insights to inform investment strategies, along with custody services to help companies, shareholders, institutions and accredited investors confidently navigate and transact in the private market.